In phase 3 trials in people with HIV-associated lipodystrophy, deep visceral fat fell by roughly 15–18% over 26 weeks of tesamorelin.
Approximate trajectory; deep visceral adipose tissue relative to baseline.
Search peptides — top sellers first
Search peptides — top sellers first
Search peptides — top sellers first
Stabilised GHRH(1-44) analogue, supplied for laboratory research use only.
$119/ 10mg vial
$59.50 per vial with Buy 1, Get 1 Free
All products currently listed on this site are for research purposes only.
Frequently bought together
Related supplies, one order, one delivery.

Reconstitution Solution · 10ml
Popular

GHK-CU · 50mg

Melanotan 2 · 10mg
Most sellers show one certificate and hope you never ask again. We publish a signed report for every batch we release, tied to the lot number on your vial. Purity is an exact number, not a “passes.” If a batch fails, it never ships.

A GHRH analogue studied for prompting growth hormone with a notably targeted effect on visceral fat.
Studied for binding the GHRH receptor to prompt natural, pulse-like growth-hormone release.
Investigated in trials for shrinking deep visceral fat while sparing surface fat and insulin sensitivity.
Researched for downstream IGF-1 signalling and effects on hepatic lipid pathways.
For research use only. Mechanisms described reflect published research literature.
Anyone can show you one good report. Here is every batch of Tesamorelin we have ever released, newest first, each with its own signed report. Nothing hidden, nothing cherry-picked.
Published findings on this compound, each linked to its source. Animal and lab results are context, not claims about this product.
In phase 3 trials in people with HIV-associated lipodystrophy, deep visceral fat fell by roughly 15–18% over 26 weeks of tesamorelin.
Approximate trajectory; deep visceral adipose tissue relative to baseline.
While deep visceral fat dropped, trials reported no matching reduction in surface (subcutaneous) fat — suggesting the effect was targeted rather than general fat loss.
Relative direction of change; subcutaneous fat was not meaningfully reduced.
Pharmacology reviews report that tesamorelin raised IGF-1 by prompting growth hormone in natural pulses rather than a constant flood.
Direction of change; reported IGF-1 rise following pulsatile GH release.
Quick answers about Tesamorelin.
Test any batch at any lab you like. If it doesn't match our report, you get every dollar back. No return shipping, no forms, no arguments.